Abstract:In this study, NIH II and III chronic prostatitis did not influence the PCA3 score. Our results suggest that increased PCA3 score is unlikely to be explained by the sole chronic prostatitis and warrants prostate biopsies to eliminate prostate cancer.
“…In the first published study on the measure of the PCA3 score in patients with indication of PCa (serum PSA level 43 ng/ml), up to 37% of the 108 tested patients were diagnosed with chronic prostatitis [11]. Their median PCA3 score was not different from that of men with normal histology, and it was concluded that both kinds of patients could be grouped in a unique population of patients without cancer; similar results were obtained in other studies [12][13][14].…”
Section: Introductionsupporting
confidence: 80%
“…In a prospective study, aiming to evaluate the effect of chronic prostatitis on the PCA3 score, this biomarker was o35 in all patients with a negative biopsy [11]. This suggests that the PCA3 score could be a valuable tool in patients with elevated PSA levels and indication of chronic prostatitis/BPH, to distinguish those subjects who will benefit from prostate biopsy [11][12][13][14]. According to Vlaeminck-Guillen et al [14], an increased PCA3 score in these patients is unlikely related to chronic prostatitis/BPH, representing an additional reason for performing a biopsy.…”
“…In the first published study on the measure of the PCA3 score in patients with indication of PCa (serum PSA level 43 ng/ml), up to 37% of the 108 tested patients were diagnosed with chronic prostatitis [11]. Their median PCA3 score was not different from that of men with normal histology, and it was concluded that both kinds of patients could be grouped in a unique population of patients without cancer; similar results were obtained in other studies [12][13][14].…”
Section: Introductionsupporting
confidence: 80%
“…In a prospective study, aiming to evaluate the effect of chronic prostatitis on the PCA3 score, this biomarker was o35 in all patients with a negative biopsy [11]. This suggests that the PCA3 score could be a valuable tool in patients with elevated PSA levels and indication of chronic prostatitis/BPH, to distinguish those subjects who will benefit from prostate biopsy [11][12][13][14]. According to Vlaeminck-Guillen et al [14], an increased PCA3 score in these patients is unlikely related to chronic prostatitis/BPH, representing an additional reason for performing a biopsy.…”
“…In a study of 38 men that had either urethritis, chronic prostatitis (bacterial or abacterial) or prostadynia, all patients had a urinary PCA3 score of ≤28, suggesting that infection and/ or inflammation did not increase urinary PCA3 levels. 48 Finally, the TMPRSS2-ERG fusion occurs at a variable frequency (16-50%) in patients of different ethni cities with prostate cancer, which might decrease the sensitivity of this test in reallife patient populations. 49 Alterations in DNA methylation Development of prostate cancer is associated with alter ations in tissue of a histologically normal appearance within the peripheral zone, termed a field effect, that occur both as a peritumour response, as well as a change distant from tumour foci.…”
No guidelines currently exist that address the need for rebiopsy in patients with a negative diagnosis of prostate cancer on initial biopsy sample analysis. Accurate diagnosis of prostate cancer in these patients is often complicated by continued elevation of serum PSA levels that are suggestive of prostate cancer, resulting in a distinct management challenge. Following negative initial findings of biopsy sample analysis, total serum PSA levels and serum PSA kinetics are ineffective indicators of a need for a repeat biopsy; therefore, patients suspected of having prostate cancer might undergo several unnecessary biopsy procedures. Several alternative strategies exist for identifying men who might be at risk of prostate cancer despite negative findings of biopsy sample analysis. Use of other serum PSA-related measurements enables more sensitive and specific diagnosis and can be combined with knowledge of clinicopathological features to improve outcomes. Other options include the FDA-approved Progensa(®) test and prostate imaging using MRI. Newer tissue-based assays that measure methylation changes in normal prostate tissue are currently being developed. A cost-effective strategy is proposed in order to address this challenging clinical scenario, and potential directions of future studies in this area are also described.
“…La principale limite de cette étude est l'absence de précision sur la nature de la prostatite. Une étude récente a de fait évalué le score PCA3 chez 34 patients avec prostatite chronique documentée [56]. Le diagnostic de prostatite chronique, basé sur des éléments cliniques, a été affiné par la réalisation d'une version simplifiée du test des quatre verres de Meares-Stamey.…”
Section: Le Test Urinaire Pca3 Dans Les Prostatitesunclassified
“…Ce test comprend un massage prostatique qui peut être assimilé au toucher rectal standardisé nécessaire avant le prélèvement urinaire destiné au test PCA3 [10]. Dans l'étude, que les patients aient une prostatite chronique bactérienne (prostatite de type II), une prostatite chronique abactérienne (prostatite de type IIIa) ou une prostatodynie non inflammatoire (stade IIIb), le score urinaire PCA3 était toujours négatif (≤ 28, en moyenne à 9 ± 7, extrêmes : 1 à 28) [56]. Dans la prostatite aiguë, peu de données sont disponibles.…”
Section: Le Test Urinaire Pca3 Dans Les Prostatitesunclassified
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.